Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Letters |

Use of Stem Cells for Ischemic Cardiomyopathy—Reply

Joshua M. Hare, MD; Darcy Difede, RN; Alan W. Heldman, MD
JAMA. 2013;309(14):1458-1459. doi:10.1001/jama.2013.2893.
Text Size: A A A
Published online


In Reply: We agree with Dr Zhang and colleagues that the issue of donor characteristics for allogeneic MSC donation is important. We chose male donors aged 21 to 35 years. Donors were carefully screened medically and documented to be free of a panel of viral infections. The age cutoff was selected to optimize the chances of culture expanding sufficient quantities of MSCs for use in several recipients.

Second, regarding the tumor complication rate, we are pleased to report that no patient in the trial exhibited neoplasia or ectopic tissue formation. This is a crucial issue,1 and one suggested by rodent studies. This potential complication has not materialized in the POSEIDON population or in other studies testing MSCs2,3 in humans. Possible reasons for the apparent safety of MSCs in this regard include their limited differentiation capacity compared with pluripotent embryonic stem cells, the relatively low level of sustained engraftment, and the lower rate of cellular transformation in human cells than in rodents.1


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




April 10, 2013
Guo-You Zhang, MD; Qing-Feng Li, MD, PhD; Xiao-Bing Fu, MD, PhD
JAMA. 2013;309(14):1458-1459. doi:10.1001/jama.2013.2890.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.